We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.

Pitch Rated

53%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £211,595
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.

Pitch Rated

45%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Nebeus aims to bridge the gap between cryptocurrency and cash, providing people with instant crypto-backed cash services for everyday use. The company argues that there is an equivalent of $400 billion held in more than 55 million crypto wallets around the world which cannot be used further than keeping as an investment. It aims to change this scenario. Nebeus's core product is its 'Instant Loans' offering. It also offers users to do mobile top-ups, conduct Card2Card transfers, and send cash to Points of Sale (PoS) amongst other financial services. The company is working to come out with a 'Nebeus Mastercard' in partnership with Railsbank in Q1 of 2021. Nebeus has more than 60,000 users on its portal and has overseen transactions over £30 million to date. The company has featured in publications like The Independent, Forbes, and Bloomberg to name a few. It will use the investment for growth and marketing, the rollout of Nebeus Mastercard rollout, for growing its team, and for Research and Development (R&D).
days to go: Expired investment: £862,580
Race Space have created an endurance event directory for the 21st century that is designed to uncomplicate the online experience of finding and entering events.  
days to go: Expired investment: £111,583
QFinds is a purpose-built hiring tool that enables employers to easily and efficiently pre-screen candidates, conduct interviews and generate employment contracts. The company asserts that it is a UK government vetted 'Kickstart Scheme' representative and can get small businesses grants to hire interns having already processed over 100 job applications. QFinds claims that its app has been downloaded 2 million+ times garnering 24,000 reviews averaging 4.8/5 stars. QFinds also points out that bad hirings cost the UK up to £6.7 billion in turnover, productivity, and training. It seeks to change this and disrupt the £39 billion recruitment market. The company has partnered with notable entities like University College London, Kings College London and Brunel University London, intending to use them as strategic partners to increase job seekers signing up to and using its app. QFinds will use the investment to grow its business across different verticals.

Pitch Rated

67%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £222,866
Q Doctor aims at changing the NHS care delivery with the help of video consulting to benefit patients and clinicians. The company is focusing on delivering a model that keeps modernised NHS care free of charge for the patients. The video solution plugs NHS clinicians to the existing NHS infrastructure and allows them to connect to the NHS patients digitally. With the proceeds, Q Doctor will fulfil its strategy for 2020. It will deploy the funds into labour, development, operations, marketing, and contingency funds.

Pitch Rated

51%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £1,386,200
freemarketFX is an FCA authorised, innovative peer-to-peer currency exchange, focused on the high-value B2B commercial spot FX market.
days to go: Expired investment: £645,496
Amchara Health specialises in bringing a better approach to creating a personalised health solution tailored to a person's needs and goals. Its aim is to educate and empower people about better health choices. This residential retreat brand is developing three health & wellness applications: HealthHub360, MyAmchara, and Amchara360. In the first 12 months, the company will aim to achieve more than 100,000 downloads of the Healthhub360 application. With the proceeds, Amchara will be marketing the MyAmchara app and rebrand it. Furthermore, there will be an international development of the application to cater to Canada, Australia, and the USA.
days to go: Expired investment: £167,619
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.

Pitch Rated

52%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £200,000
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £340,928
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph